KNSA
Kiniksa Pharmaceuticals Ltd
Price:  
21.41 
USD
Volume:  
227,390.00
Bermuda | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

KNSA WACC - Weighted Average Cost of Capital

The WACC of Kiniksa Pharmaceuticals Ltd (KNSA) is 7.4%.

The Cost of Equity of Kiniksa Pharmaceuticals Ltd (KNSA) is 11.10%.
The Cost of Debt of Kiniksa Pharmaceuticals Ltd (KNSA) is 5.00%.

Range Selected
Cost of equity 8.70% - 13.50% 11.10%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 5.00% - 5.00% 5.00%
WACC 6.2% - 8.6% 7.4%
WACC

KNSA WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 1.06 1.55
Additional risk adjustments 0.0% 0.5%
Cost of equity 8.70% 13.50%
Tax rate 26.20% 27.00%
Debt/Equity ratio 1 1
Cost of debt 5.00% 5.00%
After-tax WACC 6.2% 8.6%
Selected WACC 7.4%